![](/images/graphics-bg.png)
Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients
Joint Authors
Liang, Peter
Saggi, Subodh J.
Ranganathan, Natarajan
Pechenyak, Bohdan
Weinberg, Alan
Friedman, Eli A.
Ranganathan, Pari
Vyas, Usha
Mallappallil, Mary C.
Norin, Allen J.
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-07-23
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Primary goal of this randomized, double-blind, placebo-controlled crossover study of Renadyl in end-stage renal disease patients was to assess the safety and efficacy of Renadyl measured through improvement in quality of life or reduction in levels of known uremic toxins.
Secondary goal was to investigate the effects on several biomarkers of inflammation and oxidative stress.
Methods.
Two 2-month treatment periods separated by 2-month washout and crossover, with physical examinations, venous blood testing, and quality of life questionnaires completed at each visit.
Data were analyzed with SAS V9.2.
Results.
22 subjects (79%) completed the study.
Observed trends were as follows (none reaching statistical significance): decline in WBC count (-0.51×109/L, P=0.057) and reductions in levels of C-reactive protein (-8.61 mg/L, P=0.071) and total indoxyl glucuronide (-0.11 mg%, P=0.058).
No statistically significant changes were observed in other uremic toxin levels or measures of QOL.
Conclusions.
Renadyl appeared to be safe to administer to ESRD patients on hemodialysis.
Stability in QOL assessment is an encouraging result for a patient cohort in such advanced stage of kidney disease.
Efficacy could not be confirmed definitively, primarily due to small sample size and low statistical power—further studies are warranted.
American Psychological Association (APA)
Ranganathan, Natarajan& Pechenyak, Bohdan& Vyas, Usha& Ranganathan, Pari& Weinberg, Alan& Liang, Peter…[et al.]. 2014. Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients. BioMed Research International،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-481420
Modern Language Association (MLA)
Ranganathan, Natarajan…[et al.]. Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients. BioMed Research International No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-481420
American Medical Association (AMA)
Ranganathan, Natarajan& Pechenyak, Bohdan& Vyas, Usha& Ranganathan, Pari& Weinberg, Alan& Liang, Peter…[et al.]. Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-481420
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-481420